Arcturus Therapeutics Holdings Inc. | Business Contracts

Study Support Agreement effective October 31, 2022 by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock Company (Filed With SEC on November 4, 2022)

Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended (Filed With SEC on June 24, 2022)

Description of Registrants Securities (Filed With SEC on March 1, 2022)

Lease, by and between Arcturus Therapeutics, Inc. and TPSC IX, LLC, dated September 29, 2021 (Filed With SEC on November 9, 2021)

Supply Agreement, dated August 17, 2020, between Arcturus Therapeutics, Inc. and the Israeli Ministry of Health (Filed With SEC on November 9, 2020)

Sixth Amendment to Loan and Security Agreement, dated April 19, 2022, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank (Filed With SEC on May 9, 2022)

Fifth Amendment to Loan and Security Agreement, dated October 27, 2021, by and between Arcturus Therapeutics, Inc. and Western Alliance Bank (Filed With SEC on November 9, 2021)

Technology License and Technical Support Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint... (Filed With SEC on August 10, 2021)

Framework Drug Substance Supply Agreement, signed July 29, 2021 and effective July 30, 2021, by and between Arcturus Therapeutics, Inc. and Vinbiocare Biotechnology Joint Stock... (Filed With SEC on August 10, 2021)

Arcturus Therapeutics Holdings Inc. Severance Policy for Executives (Filed With SEC on April 26, 2021)

THIRD AMENDMENT TO LEASE (Filed With SEC on March 1, 2021)

SECOND AMENDMENT TO LEASE (Filed With SEC on March 1, 2021)

Description of Registrants Securities (Filed With SEC on March 1, 2021)

Underwriting Agreement, dated December 7, 2020, by and among Arcturus Therapeutics Holdings Inc., Piper Sandler & Co., Guggenheim Securities, LLC and Wells Fargo Securities, LLC (Filed With SEC on December 8, 2020)

Fourth Amendment to Loan and Security Agreement, dated December 1, 2020 (Filed With SEC on December 7, 2020)

Manufacturing Support Agreement, dated November 7, 2020, between Arcturus Therapeutics Holdings, Inc. and the Economic Development Board of Singapore (Filed With SEC on November 9, 2020)

Underwriting Agreement, dated July 28, 2020, by and among Arcturus Therapeutics Holdings Inc., Citigroup Global Markets Inc., Guggenheim Securities, LLC, and Barclays Capital Inc (Filed With SEC on July 29, 2020)

Underwriting Agreement, dated April 16, 2020, by and between Arcturus Therapeutics Holdings Inc. and Guggenheim Securities, LLC (Filed With SEC on April 17, 2020)

Sales Agreement, dated as of March 27, 2020, between the Company and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on March 27, 2020)

Acceptance Letter, dated March 4, 2020, between Arcturus Therapeutics Holdings Inc. and the Economic Development Board of Singapore (Filed With SEC on March 16, 2020)

Lease Agreement, by and between Arcturus Therapeutics Holdings Inc. and ARE-SD Region No. 44, LLC dated February 1, 2020 (Filed With SEC on March 16, 2020)

Form of Indemnification Agreement (Filed With SEC on March 16, 2020)

Third Amendment, dated October 30, 2019, by and between Western Alliance Bank, and Arcturus Therapeutics, Inc. to the Loan and Security Agreement dated as of October 12, 2018.... (Filed With SEC on November 8, 2019)

Form of Securities Purchase Agreement, dated September 25, 2019, between the Company and the purchasers party thereto (Filed With SEC on September 27, 2019)

Letter Agreement, dated September 23, 2019, between the Company and the Placement Agent (Filed With SEC on September 27, 2019)

Termination Agreement, dated July 26, 2019, by and between Arcturus Therapeutics, Inc. and CureVac AG (Filed With SEC on August 14, 2019)

Amendment to Development and Option Agreement, dated July 26, 2019, by and between Arcturus Therapeutics, Inc. and CureVac AG (Filed With SEC on August 14, 2019)

Amendment dated as of August 1, 2019, by and between Arcturus Therapeutics, Inc. and Cystic Fibrosis Foundation to that certain Development Program Letter Agreement of May 16, 2017 (Filed With SEC on August 14, 2019)

Securities Purchase Agreement, dated August 2, 2019, between the Company and the Investor (Filed With SEC on August 5, 2019)

Securities Purchase Agreement, dated August 1, 2019, between the Company and the Investors party thereto (Filed With SEC on August 2, 2019)

Letter Agreement, dated July 26, 2019, between the Company and the Placement Agent (Filed With SEC on August 2, 2019)

Equity Purchase Agreement, dated June 18, 2019, between the Company and Ultragenyx Pharmaceutical Inc (Filed With SEC on June 20, 2019)

Third Amendment, dated June 18, 2019 to Research Collaboration and License Agreement, dated October 26, 2015, as amended on October 17, 2017 and April 20, 2018, between the... (Filed With SEC on June 20, 2019)

Registration Rights Agreement, dated June 18, 2019, between the Company and Ultragenyx Pharmaceutical Inc (Filed With SEC on June 20, 2019)

Arcturus Therapeutics Holdings Inc. (34)